RudaCure, which is developing traitement de la douleurs, has today completed the dépôt de brevet for its invention of peptides with TRPV1 inhibitory activity.
Combined with AI-based drug screening and traditional in vitro and in vivo methods, RudaCure a obtenu a group of active peptides. This is a substance patent and use dépôt de brevet for materials that demonstrate efficacy and side effect suppression in divers pain animal models.
Negotiations are underway with une entreprise nationale for recherche conjointe on these materials, and discussions are also in progress with multinational entreprises pharmaceutiques. These compounds devraient emerge as a new option in the pain market, where there is high demand for non-addictive, side-effect-free drugs.
